FDA approves rituximab biosimilar for cancer, autoimmune disordersJuly 23, 2019Lymphoma & Plasma Cell Disorders
Chemo-free combo gets high response rate in relapsed or refractory DLBCLJuly 23, 2019DLBCLLymphoma & Plasma Cell Disorders
Ibrutinib-venetoclax found highly active in hard-to-treat CLLJuly 22, 2019Leukemia, Myelodysplasia, Transplantation
CAR T-cell therapy less effective in transformed follicular lymphomaJuly 22, 2019Lymphoma & Plasma Cell DisordersDLBCL
Flavopiridol elicits poor response in mantle cell lymphoma, DLBCLJuly 18, 2019DLBCLLymphoma & Plasma Cell Disorders
On second thought, lenalidomide does improve DLBCL outcomesJuly 15, 2019DLBCLLymphoma & Plasma Cell Disorders
SC daratumumab deemed feasible for every multiple myeloma patientJuly 11, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
